<div><div></div><div><span><p><span>Evolus, Inc. reported first-quarter 2026 results with revenue up 6.7% year over year to $73.14M, narrowing its net loss to ($10.67M) and reducing diluted loss per share to ($0.16) versus ($0.3) in the year-ago quarter.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>$73.14M</span></td><td><span>$68.52M</span></td><td><span>6.7%</span></td></tr><tr><td><span>Net income²</span></td><td><span>($10.67M)</span></td><td><span>($18.89M)</span></td><td><span>43.5%</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>($0.16)</span></td><td><span>($0.3)</span></td><td><span>46.7%</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Total net revenues”. ² Reported as “Net loss”. ³ Reported as “loss per share, basic and diluted”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Revenue growth was driven by the Evolysse® launch and international expansion of Jeuveau® across the U.S., Canada, select European markets and Australia.</span></li><li><span>Company shifted commercial focus to the cash-pay aesthetic channel with loyalty programs, co‑marketing, bundles and promotions to accelerate Evolysse® adoption.</span></li><li><span>Product rollout activity: U.S. launch of Evolysse® Form and Smooth (April 2025); full Evolysse® line planned for Europe in Q2 2026, with additional approvals expected in 2026–2027.</span></li><li><span>Operational developments included opening a $30M revolving credit facility in March 2026 and ongoing EU commercialization preparation for Evolysse®.</span></li></ul><p><span>Original SEC Filing: </span>Evolus, Inc. [ EOLS ] - 10-Q - May. 04, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

EOLS

IBBQ

SBIO

LABU

<p>Evolus, Inc. reported a 6.7% year-over-year revenue increase to $73.14M for Q1 2026, with a narrowed net loss of $10.67M and diluted EPS of ($0.16). The revenue growth was attributed to the Evolysse® launch and international expansion of Jeuveau®. The company is focusing on the cash-pay aesthetic channel and plans to launch the full Evolysse® line in Europe in Q2 2026. Additionally, a $30M revolving credit facility was opened in March 2026 to support operations.</p>

TradingView

Evolus

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary